Dexamethasone Ph. Eur. — Drug Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

4 Recruiting

12 Completed trials

5 Sponsors

21 Countries

Phase III

Phase II

Phase III: 12 Phase II: 3 Phase I/II: 1

Oversight events:

3 urgent safety measures 2 unexpected events 1 corrective measure across 5 trials

View oversight register →

Indications tested

Plasma cell myeloma 2 Pneumonia 1

Sponsors using this IMP

Janssen - Cilag International 8 Glaxosmithkline Research & Development Limited 4 Celgene Corp. 2 Pfizer Inc. 1 University Of Oxford 1

All trials

16 total

A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Phase II 16 countries Pfizer Inc.
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
RECOVERY Recruiting

2023-507441-29-00 Phase III 9 countries University Of Oxford
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Phase III 14 countries Janssen - Cilag International
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Phase III 13 countries Janssen - Cilag International
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended

2023-503467-41-00 Phase III 9 countries Janssen - Cilag International
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended

2023-503441-55-00 Phase II 10 countries Janssen - Cilag International
A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended

2023-505850-16-00 Phase III 16 countries Janssen - Cilag International
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended

2023-506877-37-00 Phase III 7 countries Glaxosmithkline Research & Development Limited
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended

2023-508962-14-00 Phase III 10 countries Glaxosmithkline Research & Development Limited
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended

2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended

2023-510537-28-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended

2023-506587-13-00 Phase II 5 countries Janssen - Cilag International
A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef… Ended

2024-510799-19-00 Phase I/II 5 countries Celgene Corp.
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended

2023-509848-10-00 Phase III 7 countries Celgene Corp.

Showing 1–16 of 16 trials

← All drugs A–Z